PARP Inhibitor Ovarian Cancer Treatment

Should PARP Inhibitors be considered as part of your treatment plan?

The one-size-fits-all approach to treating cancer can leave patients wondering which treatment will work for them. In an effort to personalize care for patients, like yourself, Myriad offers genetic tests that help get the right treatment, to the right patient, at the right time.

Should PARP Inhibitors be considered as part of your treatment plan?

The one-size-fits-all approach to treating cancer can leave patients wondering which treatment will work for them. In an effort to personalize care for patients, like yourself, Myriad offers genetic tests that help get the right treatment, to the right patient, at the right time.

Sources:
  1. Ledermann et al. Lancet Oncol. (2014). 15:852-61.
  2. Kristeleit et al. Presented at European Cancer Congress 2016 (Abstract 8560
  3. Lheureux et al. J Clin Oncol (2015). 33 (suppl;abstr 5566)
  4. Yates et al. Annals of Oncology (2014) 25 (suppl_4): iv305-iv326.
  5. The Cancer Genome Atlas. Nature (2011) 474:609-615.
  6. Timms et al. Br Ca Res (2014) 16:475-483 7.
  7. Telli et al. Clin Cancer Res (2016). In Press.
  8. Intended Use: BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.

    Results of the test are used as an aid in identifying breast and ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants, who are or may become eligible for treatment with Lynparza® (olaparib). Detection of deleterious or suspected deleterious germline BRCA variants by the BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at 320 Wakara Way, Salt Lake City, UT 84108.
  9. For more detailed information about Lynparza and its safety and efficacy please go to lynparza.com
  10. For more detailed information about Zejula and its safety and efficacy please go to zejula.com
Lynparza is a registered trademark of the AstraZeneca group of companies. Zejula is a registered trademark of Tesaro, Inc. Rubraca is a trademark of Clovis Oncology, Inc